Skip to content
Screener

Novavax NVAX Long-Term Debt

Long-Term Debt at other companies

Moderna logo
ModernaMRNA
$591M—
Merck & Co. logo
Merck & Co.MRK
$53.9B+52.3%
Gilead Sciences logo
Gilead SciencesGILD
$23.83B+7.6%
Candel Therapeutics, Inc. logo
Candel Therapeutics, Inc.CADL
$1.05M+15.8%
TTR
Turn Therapeutics Inc.TTRX
$5.94M—
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$404.3M+36.5%

Other financials

Income statement

See full
Revenue$56.7M-76.3%
Gross profit$42.5M-81.0%
Operating income-$54.9M-154%
Net income-$53.4M-150%
EPS (diluted)-$0.32-152%

Balance sheet

See full
Cash & equivalents$191.5M-24.5%
Total debt$297.3M+413%
Total equity-$190.7M-607%
Total assets$955.6M-28.5%

Cash flow

See full
Operating cash flow-$72.8M+42.9%
CapEx$588.0K+11.6%
Free cash flow-$73.4M+42.7%

Valuation

See full
Market cap$1.27B+3.7%
Enterprise value$1.38B+33.6%
P/S3.1×+1.9×

Profitability

See full
Gross margin78.6%-9.6pp
Operating margin-56.6%-89.2pp
Net margin-59.9%-99.1pp
FCF margin-59%-61.5pp

Returns & leverage

See full
Return on equity-238.6%—
Debt / equity1.5×—
Current ratio2.3×0.0×

Where this comes from

Reported directly by Novavax in its filing.

Tagged under the XBRL concept us-gaap:LongTermDebt.

The source filing: Novavax’s 10-Q, filed August 6, 2026. Open the filing →

Filed
Aug 6, 2026, 7:50 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001000694-26-000018

FAQ

What is Novavax's long-term debt?
Novavax (NVAX) reported long-term debt of $291.49M in Q2 2026.
What does long-term debt mean?
Bonds, term loans, notes payable, and other borrowings with maturities beyond one year — the primary long-term financing source.

Ask your AI about Novavax's long-term debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude